31 results
8-K
EX-99.1
VRPX
Virpax Pharmaceuticals Inc
14 Aug 23
Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments
9:05am
legal defense costs related to litigation and was partially offset by an increase in salaries and wages, severance, and fees related to market assessment
8-K
EX-99.1
ubmbv i2vkwgfs
12 May 23
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments
4:10pm
S-3
EX-4.5
ab0tbpp4fdekl5li to
7 Oct 22
Shelf registration
5:01pm
S-3
EX-4.6
gyzks19
7 Oct 22
Shelf registration
5:01pm
8-K
EX-99.1
09y5fstxt
27 Jun 22
Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis
4:30pm
DEF 14A
yv6tr9 t1
15 Jun 22
Definitive proxy
5:01pm
424B4
jef f825mhh
15 Sep 21
Prospectus supplement with pricing info
4:31pm
DRS
wcgej2 6xuz
1 Sep 21
Draft registration statement
12:00am
10-K
l9h8 o2v8hcuam4x
31 Mar 21
Annual report
4:30pm